Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) presented 25 abstracts on Tumor Treating Fields (TTFields) at the SNO 2022 Annual Meeting from Nov. 16-20, highlighting significant advancements in glioblastoma treatment.
Key findings include an analysis showing TTFields therapy improved median overall survival in patients with glioblastoma, extending it to 17.6 months versus 13.1 months for those not treated. The largest safety dataset of over 23,000 high-grade glioma patients demonstrated TTFields' high tolerability.
- TTFields therapy significantly improved overall survival for glioblastoma patients (17.6 months vs. 13.1 months, P<0.001).
- Largest safety dataset (over 23,000 patients) confirms TTFields therapy is well-tolerated.
- No new safety signals identified from the long-term use of TTFields therapy.
- None.
Health economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large commercially insured population
The largest safety dataset to date of more than 23,000 patients reinforced that TTFields therapy is well-tolerated in patients with high-grade gliomas
ROOT,
New research in HEOR includes an analysis by a coalition of researchers at Central Brain Tumor Registry of
A presentation by
A presentation highlighting TTFields therapy as a treatment for newly diagnosed GBM includes the first results of the PriCoTTF phase 1/2 study, which met its primary endpoint demonstrating the safety and tolerability of TTFields concomitant with radiotherapy, presented by
“We are honored and proud of the volume and depth of TTFields research featured at the SNO 2022 Annual Meeting,” said
ABSTRACTS
All poster presentations will occur from
CLINICAL STUDIES
(INNV-10) Overcoming challenges and optimizing patient outcomes with Tumor Treating Fields (TTFields) therapy. Lead author and presenter:
(INNV-07) Tumor Treating Fields (TTFields; 200 kHz) post-marketing safety data from patients with glioblastoma treated between 2011–2022. Lead author and presenter:
(INNV-11) Eighteen Years of Experience with Treatment of Glioblastoma Using Tumor Treating Fields (TTFields) in Newly Diagnosed Glioblastoma (ndGBM) in a single center. Lead author and presenter:
(NCOG-22) TIGER PRO-Active Study: Investigating daily activity, sleep and neurocognitive functioning in glioblastoma patients applying TTFields therapy in
(RADT-17) A case of recurrent glioblastoma effectively treated with tumor-treating-fields. Lead author and presenter:
(INNV-22) A case report of multiple lesions disappearing after TMZ+TTFields+ Darafenib and trametinib in a patient with GBM. Lead author and presenter: Boning Cai.
(INNV-30) Retrospective analysis of TTFields in patients with HGG based on the criteria of 2021 WHO CNS5. Lead author:
(RADT-18) Particle Beam Radiation Therapy plus Tumor Treating Fields in the Treatment of Newly Diagnosed WHO Grade 4 Gliomas: An Early Result of Phase 2 Single-arm Trial. Lead author and presenter:
(CTNI-47) Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients. Lead author: Chunjui Chen. Presenter:
(CTIM-05) Final results of 2-THE-TOP: a pilot phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma (ndGBM). Lead author and presenter:
(CTNI-29) Investigating safety and efficacy of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma - first results of the PriCoTTF phase I/II trial. Lead author:
(INNV-09) Impact of Molecular markers on treatment outcome of Glioblastoma patients treated with concurrent Tumor-Treating Fields (TTF) and chemoradiation: secondary analysis of SPARE trial. Lead author and presenter:
(RADT-19) Chemoradiation (CRT) treatment with or without concurrent Tumor-Treating Fields (TTFields) in patients with newly diagnosed glioblastoma (GBM). Lead author and presenter:
PRECLINICAL STUDIES
(
(DNAR-10) The efficacy of temozolomide and lomustine in glioblastoma cell lines may be enhanced by concomitant treatment with Tumor Treating Fields (TTFields). Lead author:
(EXTH-72) TTFields enhance the antineoplastic activity of the drug-repurposing approach CUSP9v3 in glioblastoma in vitro. Lead author:
(CCRG-04) Targeting the cell-cycle effects of Tumor Treating Fields (TTFields) to increase its efficacy. Lead author:
(DNAR-12) Combining Tumour Treating Fields with therapeutic DNA damage response inhibitors to increase potency in high-grade glioblastomas using clinically relevant ex-vivo glioma stem cell models. Lead author:
INNOVATION
(MODL-07) Sensitivity of Tumor Treating Fields (TTFields) treatment planning to tumor segmentation errors. Lead author: Oshrit Ze’evi. Presenter:
(MODL-13) Sensitivity of Tumor Treating Fields (TTFields) treatment planning to healthy tissue segmentation inaccuracies. Lead author: Oshrit Ze’evi. (Abstract only)
(MODL-21) Efficacy of different layouts in treating infratentorial tumors with Tumor Treating Fields (TTFields). Lead author:
(EXTH-05) Toward
(NIMG-69) Prediction of Progression-Free Survival in Patients with Primary Glioblastoma: MRI T2 Relaxivity and
HEALTH ECONOMICS AND OUTCOMES RESEARCH
(QOL-21) Real-world quality-of-life and health utilities for patients with CNS cancers on the XCELSIOR platform. Lead author:
(EPID-06) Improvements in survival for glioblastoma in the post-Stupp protocol era. Lead author:
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005144/en/
Investors:
investorinfo@novocure.com
610-723-7427
Media:
media@novocure.com
610-723-7428
Source: Novocure
FAQ
What were the main findings about TTFields therapy presented at the SNO 2022 Annual Meeting for Novocure (NVCR)?
How many abstracts did Novocure (NVCR) present at the SNO 2022 Annual Meeting?
What safety data was highlighted for TTFields therapy at the SNO 2022 Annual Meeting?